Texas Capital Bancshares Inc. TX Purchases 588 Shares of Johnson & Johnson (NYSE:JNJ)

Texas Capital Bancshares Inc. TX lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 25.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,892 shares of the company’s stock after acquiring an additional 588 shares during the period. Johnson & Johnson makes up approximately 0.7% of Texas Capital Bancshares Inc. TX’s portfolio, making the stock its 27th largest position. Texas Capital Bancshares Inc. TX’s holdings in Johnson & Johnson were worth $403,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Billeaud Capital Management Inc. increased its holdings in Johnson & Johnson by 0.4% in the 2nd quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock valued at $6,130,000 after acquiring an additional 169 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in Johnson & Johnson by 29.1% in the 4th quarter. Meeder Asset Management Inc. now owns 98,256 shares of the company’s stock valued at $12,679,000 after acquiring an additional 22,157 shares during the last quarter. Archford Capital Strategies LLC increased its holdings in Johnson & Johnson by 11.2% in the 2nd quarter. Archford Capital Strategies LLC now owns 21,997 shares of the company’s stock valued at $3,064,000 after acquiring an additional 2,211 shares during the last quarter. Freestone Capital Holdings LLC increased its holdings in Johnson & Johnson by 8.3% in the 4th quarter. Freestone Capital Holdings LLC now owns 25,526 shares of the company’s stock valued at $3,294,000 after acquiring an additional 1,954 shares during the last quarter. Finally, Hanson & Doremus Investment Management increased its holdings in Johnson & Johnson by 2.8% in the 2nd quarter. Hanson & Doremus Investment Management now owns 13,376 shares of the company’s stock valued at $1,863,000 after acquiring an additional 370 shares during the last quarter. 66.78% of the stock is owned by institutional investors.

Johnson & Johnson stock traded up $0.78 during trading hours on Friday, hitting $131.07. The company had a trading volume of 6,573,218 shares, compared to its average volume of 7,695,500. The company has a market cap of $343.86 billion, a price-to-earnings ratio of 16.02, a P/E/G ratio of 2.20 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.13 and a current ratio of 1.33. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99. The business’s 50-day simple moving average is $136.70.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The company had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. During the same period in the previous year, the company earned $2.10 EPS. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a $0.95 dividend. The ex-dividend date is Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.90%. Johnson & Johnson’s payout ratio is presently 46.45%.

JNJ has been the topic of a number of research reports. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Raymond James reduced their target price on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a report on Wednesday, July 17th. Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a report on Tuesday, May 28th. They issued a “buy” rating on the stock. Barclays assumed coverage on shares of Johnson & Johnson in a report on Friday, June 21st. They issued a “hold” rating and a $140.00 target price on the stock. Finally, Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Thursday, July 18th. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Johnson & Johnson has an average rating of “Buy” and an average target price of $148.56.

In other news, Director Marillyn A. Hewson acquired 3,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, June 11th. The stock was purchased at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the purchase, the director now directly owns 3,000 shares in the company, valued at approximately $419,040. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.23% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Treasury Bonds

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.